Enzyme-free miRNA multi-target detection method of PhC coupled FRET (Fluorescence Resonance Energy Transfer)
Through the coupled photonic crystal labeling strategy of fluorescence resonance energy transfer system, combined with enzyme-free target amplification, the problems of slow speed, low sensitivity and poor stability of existing miRNA multi-target detection methods are solved, and high sensitivity of breast cancer-related miRNAs are achieved. High specificity detection provides a new diagnosis method for breast cancer.
Patent Information
- Application Number
- CN202411217297.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-02
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-09-02
AI Technical Summary
The existing multi-target detection methods of miRNA have problems such as slow detection speed, low sensitivity, poor repeatability and limited signal response. Especially in the diagnosis of breast cancer, there is no combination of miRNA-21, miRNA-155 and miRNA-10b. Test reports, and the existing detection methods for combining PhC with FRET are mostly enzyme-containing systems, which have insufficient stability and repeatability.
The coupled photonic crystal labeling strategy of fluorescence resonance energy transfer system is adopted to combine the hairpin structure of the donor-acceptor probe with the photonic crystal to achieve enzyme-free target amplification, and the miRNA content is detected with high sensitivity through different Photonic crystal design improves detection specificity and accuracy.
Achieve high sensitivity and specificity detection of miRNA-21, miRNA-155 and miRNA-10b, simplifying the detection process, reducing costs, improving detection performance, and verifying the high accuracy and anti-interference of the method in serum sex.
Smart Images

Figure CN118932022A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a PhC-coupled FRET enzyme-free miRNA multi-target detection method, belonging to the technical fields of analytical chemistry and biomedicine. Background Art
[0002] Breast cancer is a pathological condition of the breast characterized by a high degree of morphological and molecular heterogeneity. The "2020 Global Cancer Statistics" pointed out that in 2020, breast cancer surpassed lung cancer for the first time to become the most diagnosed malignant tumor and the leading cause of disability and death in women. As a type of cancer with a significantly higher survival rate in the early stage than in the late stage, about 70%-80% of patients with early non-metastatic breast cancer can be cured. Early diagnosis and increased breast cancer detection rates mean that more breast cancer patients can achieve early detection and early treatment, thereby reducing the impact of breast cancer on human health. Therefore, it is urgent to develop a fast, simple and highly accurate diagnostic method for breast cancer.
[0003] MicroRNA (miRNA) is a class of short non-coding single-stranded RNAs, ranging from 19 to 25 nucleotides in length, that play an important role in regulating gene expression, cell differentiation, and cell proliferation. At the same time, miRNAs are considered to be ideal biomarkers for early tumor diagnosis because they play a vital role in various physiological activities associated with various cancers, such as breast cancer, lung cancer, gastric cancer, prostate cancer, colon cancer, brain cancer, and esophageal cancer. In patients with breast cancer, miRNAs show significant overexpression. Specifically, miRNA-21, miRNA-155, and miRNA-10b have been shown to be overexpressed in large quantities in patients with breast cancer. However, there are currently no reports on the combined use of these miRNAs for the diagnosis or detection of breast cancer. The simultaneous detection of multiple miRNAs is of great significance for understanding the functions of miRNAs and achieving reliable clinical diagnosis of breast cancer.
[0004] Most multi-target detection relies on molecular binding or recognition, which requires the molecules to be encoded to distinguish different processes. The most popular molecular encoding method is planar arrays, in which probe molecules are fixed on a substrate with positional coordinates as encoding elements. However, this method is often limited by the molecular binding kinetics on the substrate, resulting in prolonged assay times. Recently, suspension arrays have emerged as a promising encoding method, which utilizes elements such as fluorescent dyes, quantum dots, vibrational signals, discrete metal layers, photonic crystals, or radio frequency. Compared with planar arrays, suspension arrays have the advantages of fast detection speed, high sensitivity, and good reproducibility. In addition, suspension array detection requires a smaller sample volume and lower cost. Among various suspension arrays, spectrally encoded suspension arrays have been widely used due to their simple encoding and detection mechanisms. Although fluorescent dyes and quantum dots are the main spectral encoding elements, fluorescent dyes are easily quenched or faded, while quantum dots often exhibit biological toxicity. In addition, other commonly used encoding elements, such as electrochemical tags and Raman dyes, face limitations such as the limited number of distinguishable labels in the signal response and the potential spectral overlap between concurrent signals. Therefore, non-fluorescent encoding elements combined with single signal response methods are urgently needed to achieve multi-target detection.
[0005] Photonic crystal (PhC) is a periodic dielectric structure with photonic band gap (PBG) characteristics. PBG refers to the phenomenon that wavelengths within a specific frequency range cannot propagate through a periodic structure. Colloidal PhC is a substance with a three-dimensional ordered structure formed by dispersed micron or submicron inorganic or organic particles. These three-dimensional ordered structures enable Bragg diffraction of visible light (400-700nm), showing different colors. The encoding ability of colloidal PhC stems from the periodicity of its structure, making it resistant to fading, bleaching, quenching, and chemical instability. These characteristics improve the reliability of colloidal PhC encoding. Using fluorescence resonance energy transfer ( PhC and FRET have several advantages in detecting biological targets, including cost-effectiveness, simple procedures, good stability, sensitive detection, and compatibility with various nanomaterial platforms. Efficient FRET relies on precise control of the distance between the donor and acceptor fluorescent dyes, because their absorption and emission spectra must overlap during the energy transfer process. Based on the advantages mentioned above, if the two technologies can be combined for the detection of miRNA, it may provide a new way for efficient detection of diseases. Of course, there are also some reports on combining PhC with FRET for miRNA, but they are all enzyme-containing systems, and most of the enzymes are used in signal amplification strategies, which may face problems of poor stability and repeatability, resulting in inaccurate detection results. Summary of the invention
[0006] To solve the above technical problems, the present invention has established a multi-target detection method based on the fluorescence resonance energy transfer system coupled with the photonic crystal labeling strategy. The FRET ratio is highly sensitive to small changes in the donor-acceptor separation. At the same time, the non-auxiliary enzyme target amplification strategy is combined to make the technical design more stable, simple, and fast to detect, with better detection performance. Combined with different PhC designs, it can be used for miRNA multi-target detection, and the method has been verified by serum testing to have high sensitivity, high specificity and accuracy.
[0007] The first object of the present invention is to provide an application of a miRNA detection system in the preparation of a diagnostic product, the application comprising the following steps:
[0008] S1, preparing the donor probe and the acceptor probe into hairpin structures respectively;
[0009] S2, fixing the donor probe on the photonic crystal, incubating with the acceptor probe and the miRNA target of known concentration, and performing enzyme-free amplification;
[0010] S3, after the amplification is completed, fluorescence resonance energy transfer detection is performed to establish a relationship curve between the fluorescence intensity ratio and the miRNA target content;
[0011] S4, repeating steps S1 to S3 for the sample to be tested, calculating the content of the miRNA target by the fluorescence intensity ratio of the sample to be tested, and obtaining a diagnosis result according to the content of the miRNA target;
[0012] The miRNA target includes one or more miRNAs, the donor probe includes one or more first probes, and the acceptor probe includes one or more second probes, and different first probes and second probes are designed according to different miRNA targets respectively; the photonic crystal is one or more, and the colors of light reflected by the multiple photonic crystals are different;
[0013] The donor probe is fixed on the photonic crystal, and when detecting multiple miRNA targets, different first probes are respectively fixed on photonic crystals with different colors of reflected light;
[0014] The first probe is provided with a connecting sequence, a first sequence, a second sequence, a third sequence, a fourth sequence and a connecting sequence, the second probe is provided with a sequence A, a sequence B and a sequence C, and: the second sequence is complementary to sequence C, the third sequence is complementary to sequence B, the miRNA target is complementary to the third sequence and the fourth sequence, the length of the first sequence is 10-14 bases, the length of the sequence A is 9-13 bases, and the binding free energy (ΔG) of the second probe (sequence B+sequence C) and the first probe (second sequence+third sequence) is lower than the binding free energy of the miRNA target and the first probe (third sequence+fourth sequence);
[0015] One end of the first probe close to the first sequence is modified with a donor fluorescent molecule, and the other end is connected to the photonic crystal. One end of the second probe close to sequence C is modified with an acceptor fluorescent molecule.
[0016] Furthermore, the linker sequence is 1-5 arbitrary bases, preferably 1-5 identical bases, such as 1A-5A, 1T-5T, 1G-5G, 1C-5C.
[0017] Further, the miRNA target includes one or more of miRNA-21, miRNA-155, and miRNA-10b;
[0018] When the miRNA target includes miRNA-21, the donor probe includes the first sequence shown in SEQ ID NO.1, and / or the acceptor probe includes the second sequence shown in SEQ ID NO.4,
[0019] When the miRNA target includes miRNA-155, the donor probe includes the first sequence shown in SEQ ID NO.2, and / or the acceptor probe includes the second sequence shown in SEQ ID NO.5,
[0020] When the miRNA target includes miRNA-10b, the donor probe includes the first sequence shown in SEQ ID NO.3, and / or the acceptor probe includes the second sequence shown in SEQ ID NO.6.
[0021] Further, regarding the modification of the fluorescent molecule, it is preferred that:
[0022] When the first sequence is as shown in SEQ ID NO.1, the donor fluorescent molecule is modified at the 3' end, and / or when the second sequence is as shown in SEQ ID NO.4, the acceptor fluorescent molecule is modified at the 5' end;
[0023] When the first sequence is as shown in SEQ ID NO.2, the donor fluorescent molecule is modified at the 5' end, and / or when the second sequence is as shown in SEQ ID NO.5, the acceptor fluorescent molecule is modified at the 3' end;
[0024] When the first sequence is as shown in SEQ ID NO.3, the donor fluorescent molecule is modified at the 3' end, and / or when the second sequence is as shown in SEQ ID NO.6, the acceptor fluorescent molecule is modified at the 5' end.
[0025] Furthermore, the diagnostic product is a breast cancer diagnostic product. Specifically, the result of the sample to be tested is compared with the result of the healthy sample. If the miRNA content (or FRET ratio) of the sample to be tested is higher than that of the healthy sample, it indicates that the patient may be a breast cancer patient or a high-risk population.
[0026] Furthermore, the selection of donor-acceptor fluorescent molecule pairs includes but is not limited to FAM-ROX, CFP (cyan fluorescent protein)-YFP (yellow fluorescent protein), BFP (blue fluorescent protein)-GFP, BFP-YFP, Cy3-Cy5, FITC (fluorescein isothiocyanate)-Rhodamine, etc.
[0027] Further, incubation was performed at 20-30°C.
[0028] Furthermore, the concentration of the miRNA is 1 pM-10000 pM. In the present invention, when the miRNA content of untreated human serum is measured, the minimum sample volume is only 1 μL, and miRNA-21, miRNA-155 and miRNA-10b in different serum samples can be qualitatively and quantitatively analyzed.
[0029] Furthermore, photonic crystals can reflect light of different colors through photonic band gap, nanoscale adjustment and other methods.
[0030] The second object of the present invention is to provide a miRNA detection probe composition, wherein the miRNA detection probe composition comprises a donor probe and an acceptor probe, wherein the donor probe and the acceptor probe are hairpin structures;
[0031] The donor probe includes one or more first probes, and the acceptor probe includes one or more second probes, and different first probes and second probes are designed according to different miRNAs respectively;
[0032] The first probe is provided with a connecting sequence, a first sequence, a second sequence, a third sequence, a fourth sequence and a connecting sequence, the second probe is provided with a sequence A, a sequence B and a sequence C, and: the second sequence is complementary to sequence C, the third sequence is complementary to sequence B, the miRNA is complementary to the third sequence and the fourth sequence, the length of the first sequence is 10-14 bases, the length of the sequence A is 9-13 bases, and the binding free energy (ΔG) of the second probe (sequence B+sequence C) and the first probe (second sequence+third sequence) is lower than the binding free energy of the miRNA and the first probe (third sequence+fourth sequence);
[0033] The end of the first probe close to the first sequence is modified with a donor fluorescent molecule, and the end of the second probe close to sequence C is modified with an acceptor fluorescent molecule.
[0034] Further, the miRNA target includes one or more of miRNA-21, miRNA-155, and miRNA-10b;
[0035] When the miRNA target includes miRNA-21, the donor probe includes the first sequence shown in SEQ ID NO.1, and / or the acceptor probe includes the second sequence shown in SEQ ID NO.4,
[0036] When the miRNA target includes miRNA-155, the donor probe includes the first sequence shown in SEQ ID NO.2, and / or the acceptor probe includes the second sequence shown in SEQ ID NO.5,
[0037] When the miRNA target includes miRNA-10b, the donor probe includes the first sequence shown in SEQ ID NO.3, and / or the acceptor probe includes the second sequence shown in SEQ ID NO.6.
[0038] Further, regarding the modification of the fluorescent molecule, it is preferred that:
[0039] When the first sequence is as shown in SEQ ID NO.1, the donor fluorescent molecule is modified at the 3' end, and / or when the second sequence is as shown in SEQ ID NO.4, the acceptor fluorescent molecule is modified at the 5' end;
[0040] When the first sequence is as shown in SEQ ID NO.2, the donor fluorescent molecule is modified at the 5' end, and / or when the second sequence is as shown in SEQ ID NO.5, the acceptor fluorescent molecule is modified at the 3' end;
[0041] When the first sequence is as shown in SEQ ID NO.3, the donor fluorescent molecule is modified at the 3' end, and / or when the second sequence is as shown in SEQ ID NO.6, the acceptor fluorescent molecule is modified at the 5' end.
[0042] The third object of the present invention is to provide a miRNA detection system, wherein the miRNA detection system comprises a miRNA detection probe composition and a photonic crystal:
[0043] The donor probe is fixed on the photonic crystal and fixed on the end of the first probe away from the donor fluorescent molecule; the photonic crystal is one or more types, and the colors of light reflected by the multiple photonic crystals are different.
[0044] The fourth object of the present invention is to provide the use of the miRNA detection probe composition or miRNA detection system in the preparation of miRNA detection products.
[0045] The fifth object of the present invention is to provide a diagnostic product, wherein the diagnostic product contains the miRNA detection probe composition or miRNA detection system.
[0046] Furthermore, depending on the type of miRNA detected, the diagnostic products include but are not limited to diagnostic products for cancer (including but not limited to breast cancer, cervical cancer, prostate cancer, colorectal cancer, lung cancer, liver cancer, gastric cancer, pancreatic cancer, etc.), cardiovascular disease, neurodegenerative disease, viral infection, muscle disease, liver disease, autoimmune disease, etc.
[0047] By means of the above scheme, the present invention has at least the following advantages:
[0048] The present invention designs a miRNA (multi-target) detection method of a fluorescence resonance energy transfer system coupled with a photonic crystal labeling strategy, which can be used for highly sensitive and highly specific detection of at least miRNA-21, miRNA-155 and miRNA-10b. By preparing different PhCs for multi-target qualitative analysis, the donor probes on the surfaces of different PhCs are modified to specifically recognize the target miRNA, and the miRNA opens the donor probe hairpin structure, thereby forming a partial double-stranded complementary structure between the donor probe and the miRNA, and exposing the foothold of the donor probe. The receptor probe can bind to the foothold and form a double strand with the donor probe, so that the miRNA is competed off and the signal amplification process is carried out. This cyclic process is repeated in the periodic miRNA recognition system and the enzyme-free amplification reaction, thereby achieving efficient signal amplification. The constructed enzyme-assisted target amplification system does not need to add auxiliary enzymes and fuel chains during the reaction process, and the signal release and signal amplification process can be spontaneously completed after the target is recognized, which greatly simplifies the detection process, reduces the detection cost and improves the detection sensitivity.
[0049] The above description is only an overview of the technical solution of the present invention. In order to more clearly understand the technical means of the present invention and implement it according to the contents of the specification, the following is a description of the preferred embodiments of the present invention in conjunction with detailed drawings. BRIEF DESCRIPTION OF THE DRAWINGS
[0050] Figure 1 This is a schematic diagram of the multi-target miRNA detection method based on the fluorescence resonance energy transfer system coupled with photonic crystal labeling.
[0051] Figure 2 Standard curve for miRNA-21 detection.
[0052] Figure 3 Standard curve for miRNA-155 detection.
[0053] Figure 4 This is the standard curve for miRNA-10b detection.
[0054] Figure 5 This is the application result of the multi-target detection method in actual serum samples.
[0055] Figure 6 Comparison of detection effects of different probes. DETAILED DESCRIPTION
[0056] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.
[0057] The scheme and principle involved in the present invention are as follows:
[0058] The present invention provides a method for detecting multiple miRNA multi-targets in various cancers including breast cancer by coupling a fluorescence resonance energy transfer system with a photonic crystal labeling strategy: first, SiO2 with different diameters is used as a water phase, and dimethyl silicone oil with a viscosity of 10 cs is used as an oil phase to synthesize PhC with different reflected light in a droplet microfluidic system. An ethanol solution containing a silane coupling agent ((3-Aminopropyl)triethoxysilane, APTE) is used to modify the surface of PhC with NH2, and after washing with a PBS buffer, the amino-modified PhC is added to a PBS buffer containing glutaraldehyde to make the amino and aldehyde groups on the surface of PhC form an aldehyde-amine condensation reaction, thereby modifying the aldehyde group on the surface of PhC. A donor hairpin sequence is added to the aldehyde-modified PhC, and a strong FAM fluorescence signal is generated on the surface of PhC. The donor sequence is connected to the surface of PhC through the amino-aldehyde group, and the donor sequence can specifically recognize miRNA and be opened by miRNA. NaBH4 is used to block the redundant sites on the surface of PhC after the probe is fixed to avoid the nonspecific adsorption of DNA. When miRNA is present, the specifically recognized donor sequence can be opened and expose the foothold, and the acceptor sequence can compete with the target miRNA by binding to the foothold of the donor sequence, thereby realizing the target enzyme-free amplification process and forming a donor-acceptor double chain for FRET. At this time, under the excitation of the fluorescent donor excitation wavelength, the fluorescence intensity of the fluorescent acceptor increases and the fluorescence intensity of the fluorescent donor decreases. Finally, a linear relationship between the FRET ratio and the miRNA concentration is established, and the miRNA content in the sample is calculated using the standard curve.
[0059] Example 1 Construction of detection system
[0060] The sequences involved in this embodiment are shown in the table below.
[0061]
[0062] The specific steps are as follows:
[0063] (1) Preparation of PhC
[0064] In a microfluidic device connected by a "T" tube, 10cs dimethyl silicone oil is used to shear different SiO2 aqueous phases into droplets, wherein the flow rate of 10cs dimethyl silicone oil is set to 6mL / h and the flow rate of SiO2 aqueous solution is set to 1mL / h. Then, these droplets are collected in a container filled with 500cs of high-viscosity dimethyl silicone oil. After evaporation at 80°C overnight and cleaning with n-hexane to remove residual silicone oil, PhC is calcined at 550°C for 4h. Among them, the diameters of SiO2 are: 212.9nm, 240.8nm and 255.7nm, respectively. The present invention changes the color of the emitted light by changing the nanoscale, and the reflected light colors presented by different PhCs are blue, green and red, respectively.
[0065] (2) Immobilization of donor probe
[0066] After PhC was soaked in piranha solution (30% hydrogen peroxide and 70% sulfuric acid, v / v) overnight, it was rinsed with water and then dried with a nitrogen stream. PhC was treated with 5% APTE in ethanol for 4 hours to introduce NH2 groups on the surface of PhC. After that, the surface of PhC was modified with aldehyde groups, and the amino-functionalized PhC was dispersed in PBS buffer containing 2.5% glutaraldehyde, reacted at 37°C for 4 hours, and then washed with PBS buffer. After the donor probe was denatured at 95°C for 5 minutes, it was gradually annealed to room temperature to form a hairpin structure. PhC reacted with the donor probe in PBS buffer at 4°C for 12 hours, and then the remaining aldehyde groups on the surface of PhC were blocked with 20mM glycine (Gly) blocking agent at 37°C for 2 hours. The probe-modified PhC was stored at 4°C before use. Among them, the fluorescent donor sequence HP for detecting miRNA-21 1-1 Fixed on blue PhC, fluorescent receptor sequence is HP 1-2 , detecting the fluorescent donor sequence HP of miRNA-155 2-1 Fixed on green PhC, fluorescent receptor sequence is HP 2-2 , detecting the fluorescent donor sequence HP of miRNA-10b 3-1 Fixed on red PhC, fluorescent receptor sequence is HP 3-2 .
[0067] (3) Determination of multiple miRNAs
[0068] The donor probe modified PhC was added to PBS buffer. Subsequently, the acceptor probe was heated at 95°C for 5 minutes for denaturation, then slowly annealed to room temperature to form a hairpin structure, and then introduced into the reaction system. 1 μL of miRNA samples of different concentrations were added and incubated at room temperature. After incubation, the samples were washed with PBS buffer and the fluorescence intensity was measured. The fluorescence values were counted through the color camera channel and the corresponding fluorescence values, and the relationship between the FRET ratio (F2 / F1) and the miRNA concentration was calculated. Among them, the donor probes for detecting miRNA-21, miRNA-155, and miRNA-10b were HP 1-1 , HP 2-1 and HP 3-1 , the receptor probes are HP 1-2 , HP 2-2 and HP 3-2 Two channels were set up for measuring fluorescence intensity: channel 1 (F1) with an excitation wavelength of 495 nm and an emission wavelength of 515-545 nm; channel 2 (F2) with an excitation wavelength of 495 nm and an emission wavelength of 595-625 nm.
[0069] (4) Plotting of miRNA concentration standard curve
[0070] According to the relationship between the fluorescence signal and the concentration of miRNA-21, the corresponding linear relationship curve was drawn. Figure 2 As shown in Figure 2, the fluorescence intensity increases with the increase of miRNA-21 concentration, and its linear regression equation is y=0.0201*log x+0.338, R 2 is 0.992, where y represents the FRET ratio and x represents the miRNA-21 concentration (pM). The detection limit of this method is 6.36 fM.
[0071] According to the relationship between the fluorescence signal and the concentration of miRNA-155, the corresponding linear relationship curve was drawn. Figure 3 As shown in Figure 2, the fluorescence intensity increases with the increase of miRNA-155 concentration, and its linear regression equation is y=0.0172*log x+0.359, R 2 is 0.992, where y represents the FRET ratio and x represents the miRNA-155 concentration (pM). The detection limit of this method is 8.52 fM.
[0072] According to the relationship between the fluorescence signal and the concentration of miRNA-10b, the corresponding linear relationship curve was drawn. Figure 4 As shown in Figure 2, the fluorescence intensity increases with the increase of miRNA-10b concentration, and its linear regression equation is y=0.0333*log x+0.369, R 2is 0.998, where y represents the FRET ratio and x represents the miRNA-10b concentration (pM). The detection limit of this method is 6.06 fM.
[0073] Example 2 Multi-target detection application
[0074] The following demonstrates the application of the detection system of the present invention in actual serum sample detection, where the sample is untreated serum from breast cancer patients.
[0075] Three PhCs with different characteristic reflection peaks, 456.73 nm (blue), 530.07 nm (green), and 632.79 nm (red), were used to quantitatively analyze the three miRNAs simultaneously ( Figure 5 ). Using donor probe HP 1-1 , HP 2-1 and HP 3-2 Blue PhC, green PhC, and red PhC were modified to specifically recognize three different targets. Subsequently, the receptor probe HP was introduced under the same conditions. 1-2 , HP 2-2 and HP 3-2 Co-incubation. By specifically binding the target to the corresponding probe, after enzyme-free amplification, it was observed that the fluorescence intensity of channel 1 on the PhC connected to the matching miRNA target decreased, and the fluorescence intensity of channel 2 increased. At the same time, the FRET ratio (F2 / F1) value increased, and the results were as follows Figure 5 shown.
[0076] These results indicate that the combination of miRNA-triggered enzyme-free amplification and PhC technology has high specificity, sensitivity, and anti-interference, and is expected to be used in clinical detection of multiple miRNAs. This strategy has the potential to become a new platform for performing multiple biomarker analyses and facilitating disease diagnosis.
[0077] Example 3
[0078] The sequence information involved in this embodiment is as follows:
[0079]
[0080] The target detected in this example is miRNA-155, and two groups of experiments are set up. Group 1: donor hairpin HP 2-1 HP 2-2 , Group 2: Donor hairpin HP 2-1-2 HP 2-2-2 , the detection process is the same as the above embodiment.
[0081] The results are as follows Figure 6As shown, the FRET ratio of group 1 is significantly higher than that of group 2, which shows that the modification of the donor molecule and the acceptor molecule has a certain influence on the detection effect.
[0082] Obviously, the above embodiments are merely examples for clear explanation and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived from these are still within the protection scope of the invention.
Claims
1. Application of a miRNA detection system in the preparation of a miRNA detection product, characterized in that: The miRNA detection system includes a donor probe, an acceptor probe and a photonic crystal, and the application includes the following steps: S1, preparing the donor probe and the acceptor probe into hairpin structures respectively; S2, fixing the donor probe on the photonic crystal, incubating with the acceptor probe and the miRNA target of known concentration, and performing enzyme-free amplification; S3, after the amplification is completed, fluorescence resonance energy transfer detection is performed to establish a relationship curve between the fluorescence intensity ratio and the miRNA target content; S4, repeating steps S1 to S3 for the sample to be tested, calculating the content of the miRNA target by the fluorescence intensity ratio of the sample to be tested, and obtaining a diagnosis result according to the content of the miRNA target; The miRNA target includes one or more miRNAs, the donor probe includes one or more first probes, and the acceptor probe includes one or more second probes, and different first probes and second probes are designed according to different miRNA targets respectively; the photonic crystal is one or more, and the colors of light reflected by the multiple photonic crystals are different; The donor probe is fixed on the photonic crystal, and when detecting multiple miRNA targets, different first probes are respectively fixed on photonic crystals with different colors of reflected light; The first probe is provided with a connecting sequence, a first sequence, a second sequence, a third sequence, a fourth sequence and a connecting sequence, the second probe is provided with a sequence A, a sequence B and a sequence C, and: the second sequence is complementary to sequence C, the third sequence is complementary to sequence B, the miRNA target is complementary to the third sequence and the fourth sequence, the length of the first sequence is 10-14 bases, the length of the sequence A is 9-13 bases, and the binding free energy of the second probe to the first probe is lower than the binding free energy of the miRNA target to the first probe; One end of the first probe close to the first sequence is modified with a donor fluorescent molecule, and the other end is connected to the photonic crystal. One end of the second probe close to sequence C is modified with an acceptor fluorescent molecule.
2. The use according to claim 1, characterized in that: The miRNA target includes one or more of miRNA-21, miRNA-155, and miRNA-10b; When the miRNA target includes miRNA-21, the donor probe includes the first sequence shown in SEQ ID NO.1, and / or the acceptor probe includes the second sequence shown in SEQ ID NO.4, When the miRNA target includes miRNA-155, the donor probe includes the first sequence shown in SEQ ID NO.2, and / or the acceptor probe includes the second sequence shown in SEQ ID NO.5, When the miRNA target includes miRNA-10b, the donor probe includes the first sequence shown in SEQ ID NO.3, and / or the acceptor probe includes the second sequence shown in SEQ ID NO.
6.
3. The use according to claim 2, characterized in that: When the first sequence is as shown in SEQ ID NO.1, the donor fluorescent molecule is modified at the 3' end, and / or when the second sequence is as shown in SEQ ID NO.4, the acceptor fluorescent molecule is modified at the 5' end; When the first sequence is as shown in SEQ ID NO.2, the donor fluorescent molecule is modified at the 5' end, and / or when the second sequence is as shown in SEQ ID NO.5, the acceptor fluorescent molecule is modified at the 3' end; When the first sequence is as shown in SEQ ID NO.3, the donor fluorescent molecule is modified at the 3' end, and / or when the second sequence is as shown in SEQ ID NO.6, the acceptor fluorescent molecule is modified at the 5' end.
4. The use according to claim 1, characterized in that: The selection of donor-acceptor fluorescent molecule pairs includes FAM-ROX, CFP-YFP, BFP-GFP, BFP-YFP, Cy3-Cy5, and FITC-Rhodamine.
5. A miRNA detection probe composition, characterized in that: The miRNA detection probe composition includes a donor probe and an acceptor probe, wherein the donor probe and the acceptor probe are hairpin structures; The donor probe includes one or more first probes, and the acceptor probe includes one or more second probes, and different first probes and second probes are designed according to different miRNAs respectively; The first probe is provided with a connecting sequence, a first sequence, a second sequence, a third sequence, a fourth sequence and a connecting sequence, the second probe is provided with a sequence A, a sequence B and a sequence C, and: the second sequence is complementary to sequence C, the third sequence is complementary to sequence B, the miRNA is complementary to the third sequence and the fourth sequence, the length of the first sequence is 10-14 bases, the length of the sequence A is 9-13 bases, and the binding free energy of the second probe to the first probe is lower than the binding free energy of the miRNA to the first probe; The end of the first probe close to the first sequence is modified with a donor fluorescent molecule, and the end of the second probe close to sequence C is modified with an acceptor fluorescent molecule.
6. The miRNA detection probe composition according to claim 5, characterized in that: The miRNA target includes one or more of miRNA-21, miRNA-155, and miRNA-10b; When the miRNA target includes miRNA-21, the donor probe includes the first sequence shown in SEQ ID NO.1, and / or the acceptor probe includes the second sequence shown in SEQ ID NO.4, When the miRNA target includes miRNA-155, the donor probe includes the first sequence shown in SEQ ID NO.2, and / or the acceptor probe includes the second sequence shown in SEQ ID NO.5, When the miRNA target includes miRNA-10b, the donor probe includes the first sequence shown in SEQ ID NO.3, and / or the acceptor probe includes the second sequence shown in SEQ ID NO.
6.
7. A miRNA detection system, characterized in that: The miRNA detection system comprises the miRNA detection probe composition according to claim 5 or 6 and a photonic crystal; the donor probe is fixed on the photonic crystal, the photonic crystal is one or more, and the colors of light reflected by the multiple photonic crystals are different.
8. Use of the miRNA detection probe composition according to claim 5 or 6 or the miRNA detection system according to claim 7 in the preparation of a miRNA detection product.
9. A diagnostic product, characterized in that: The diagnostic product contains the miRNA detection probe composition according to claim 5 or 6 or the miRNA detection system according to claim 7.
10. The diagnostic product according to claim 9, characterized in that The diagnostic products include those for cancer, cardiovascular disease, neurodegenerative disease, viral infection, muscle disease, liver disease or autoimmune disease.
Citation Information
Patent Citations
Optical biosensor
CN107110784A
Substance detection method based on fluorescence resonance energy transfer and excision enzyme assisted cyclic amplification strategies
CN112251493A
Method for localized catalytic hairpin self-assembly amplification and fluorescence spectrum detection of cancer marker miRNA based on DNA tetrahedral probe
CN118516461A
Hemomosaic: high-throughput technique for rare cell detection in liquid samples by massively multiplexed PCR in a photolithographic matrix
US20130210646A1
Methods and compositions for multiplexed and ultrasensitive microrna detection
US20140342933A1
Cited By
Multi-marker detection method for fluorescence enhancement of aptamer-antibody dual-recognition coupled three-dimensional inverse opal hydrogel photonic crystal
CN121347465A
